doi: 10.1001/jama.2021.23619 Hinnen, D
Yajima, T., Yajima, K., Hayashi, M., Takahashi, H
[DOI] [PubMed] [Google Scholar] 10.Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
This is the first trial to demonstrate that a medication can change the clinical trajectory of the disease in patients with HFpEF and obesity.
According to research, people using GLP-1 medications lose up to 12% more body weight compared to those relying only on diet and exercise
If side effects persist or become bothersome, your clinician can pause dosing, lower your current dose, or switch you to oral semaglutide, which some patients tolerate better than injections